This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aclaris Therapeutics’s 8K filing here.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
- Five stocks we like better than Aclaris Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Insider Trading – What You Need to Know
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- DuPont Is the Unexpected Benefactor of the AI Boom
